drugset / Trial / NCT06091267

PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes

NCT06091267

Phase 1/2 Active not recruiting 72 enrolled Otsuka Beijing Research Institute
RandomizedCrossoverOpen-labelTreatment

Summary

This is an Open-Label, Crossover, Pharmacokinetic and Efficacy Bridging Study of Oral ASTX727 versus IV Decitabine in Chinese Subjects with Myelodysplastic Syndromes

Timeline

Start
2023-10-16
Primary completion
2026-05-31
Completion
2027-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject ASTX727 Unknown
Subject Decitabine Small molecule 20 mg/m2 Intravenous